A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate Cancer
Status:
Unknown status
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
The aim of this study is to investigate the clinical value of [18F]aluminum
fluoride-1,4,7-triazacyclononane-1,4,7-triacetic
acid-neurotensin（18F-AlF-NOTA-neurotensin）positron emission tomography / computed tomography
(PET/CT) in patients with prostate cancer (PCa).